Literature DB >> 32025127

Real-world effectiveness and safety of pharmacological thromboprophylaxis in patients undergoing primary total hip and knee arthroplasty: A narrative review.

Astrid Blicher Schelde1, Astrid Eliasen1, Jonas Bjerring Olesen2, Thomas Bo Jensen1, Espen Jimenez-Solem1,3.   

Abstract

In this narrative review of the real-world effectiveness and safety of pharmacological thromboprophylaxis following primary total hip and knee arthroplasty, a total of 12 non-interventional observational studies were included. Pharmacological thromboprophylaxis included warfarin, heparins, dabigatran, rivaroxaban, apixaban, acetylsalicylic acid, and fondaparinux. The absolute risks varied across the included studies. These variations can be explained by differences in patient populations, drug exposure, follow-up time, and definition of outcomes, which makes it a challenge to compare the risk estimates. These findings emphasize the need for a large population-based real-world study to provide comparable risk estimates associated with different pharmacological thromboprophylaxis.
© 2019 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug effectiveness; Drug safety; Pharmacological thromboprophylaxis; Total hip arthroplasty; Total knee arthroplasty

Year:  2019        PMID: 32025127      PMCID: PMC6997650          DOI: 10.1016/j.jor.2019.11.012

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  20 in total

1.  Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty.

Authors:  Raymond A Sachs; Jennifer H Smith; Mary Kuney; Liz Paxton
Journal:  J Arthroplasty       Date:  2003-06       Impact factor: 4.757

2.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA.

Authors:  Pål O Borgen; Ola E Dahl; Olav Reikeras
Journal:  Hip Int       Date:  2010 Jul-Sep       Impact factor: 2.135

4.  Ninety-day mortality after elective total hip replacement: 1549 patients using aspirin as a thromboprophylactic agent.

Authors:  M Parry; V Wylde; A W Blom
Journal:  J Bone Joint Surg Br       Date:  2008-03

5.  Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement.

Authors:  B V Bloch; V Patel; A J Best
Journal:  Bone Joint J       Date:  2014-01       Impact factor: 5.082

6.  Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.

Authors:  D A L King; R E Pow; D M Dickison; P R Vale
Journal:  Intern Med J       Date:  2016-09       Impact factor: 2.048

7.  The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89).

Authors:  Emma Gee
Journal:  Br J Haematol       Date:  2019-06-05       Impact factor: 6.998

8.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Authors:  Bengt I Eriksson; Lars C Borris; Richard J Friedman; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Tiemo J Bandel; Horst Beckmann; Eva Muehlhofer; Frank Misselwitz; William Geerts
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

9.  Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study.

Authors:  E Bayley; S Brown; N S Bhamber; P W Howard
Journal:  Bone Joint J       Date:  2016-05       Impact factor: 5.082

10.  Stacked Modalities' Thromboprophylactic Therapy for Patients Undergoing Total Knee Replacement Surgery.

Authors:  Limin Jiang; Shudong Zhang; Yuchi Zhao
Journal:  J Knee Surg       Date:  2016-05-23       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.